Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms JPMS-CTEPH
- Sponsors Bayer
- 24 Oct 2019 Planned number of patients changed from 420 to 1298.
- 24 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Planned End Date changed from 1 Jan 2024 to 16 Jan 2024.